Update, Johnson & Johnson shares after Guggenheim lifts target
Published on 06/28/2026 at 09:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 09:27.
Johnson & Johnson (US4781601046) enters Sunday trading with a fresh analyst note from Guggenheim and a clear New York anchor on the NYSE. Guggenheim lifted its price target to $270 from $266 and reiterated Buy, according to the June 26 note picked up by Yahoo Finance.
Guggenheim turns more upbeat
The new target is one of the cleanest fresh facts on the tape today. Yahoo Finance reported on June 28 that Guggenheim updated its model after reviewing prescription data, recent company developments and management comments since the April Q1 call. Yahoo Finance on the Guggenheim update
MarketBeat’s JNJ news feed also points to the same analyst backdrop, including a June 26 item that flagged the revised target and Buy rating. The same feed quotes a recent move in the shares, with a closing price of $254.64 on June 26, which puts Guggenheim’s new target only modestly above the last close. MarketBeat JNJ news feed
July 15 sits ahead
The next clear calendar marker is July 15, 2026, when MarketBeat lists Johnson & Johnson’s Q2 2026 earnings report. That date keeps the stock tied to a concrete event window, even before the numbers land. MarketBeat earnings calendar
Consensus data on MarketBeat shows a mean price target of $256.70 for the shares and a market cap of $613.02 billion. That places J&J among the largest healthcare names in the US market and keeps analyst expectations clustered close to the current share price.
All news and analysis on Johnson & Johnson shares
The Guggenheim note, the July 15 earnings date and the latest consensus target all point to the same stock story line.
The product behind the stock
Johnson & Johnson’s portfolio still revolves around pharmaceuticals, medtech and consumer health, with prescription drugs such as Stelara and Darzalex among the better-known revenue drivers. The company has also used acquisitions to widen its oncology pipeline, including the planned Firefly Bio deal reported by Reuters on June 8.
Johnson & Johnson on NYSE
The Johnson & Johnson shares (US4781601046) trade on the NYSE at $254.64, as of 2026-06-26, 03:59 PM Eastern.
Johnson & Johnson at a glance
- Company: Johnson & Johnson
- ISIN: US4781601046
- Ticker: JNJ
- Trading venue: NYSE
- Price (as of 2026-06-26, 03:59 PM Eastern): $254.64 USD
- Market cap: $613.02 billion USD (as of 2026-06-28)
- Sector / industry: Health Care / Pharmaceuticals, Biotechnology & Life Sciences
- Next earnings date: 2026-07-15
Disclaimer: This article is for information only and does not constitute investment advice.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
